Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

NCT04068194 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04068194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 7, 2020
Completion date
July 1, 2027
Enrollment
103 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced malignant solid neoplasm, locally advanced unresectable cholangiocarcinoma, locally advanced unresectable gallbladder carcinoma, locally advanced unresectable malignant solid neoplasm, metastatic cholangiocarcinoma, metastatic gallbladder carcinoma, metastatic malignant solid neoplasm, stage iii gallbladder cancer ajcc v8, stage iv gallbladder cancer ajcc v8, unresectable malignant solid neoplasm